Coherus Oncology
CHRS
146 hedge funds and large institutions have $1.47B invested in Coherus Oncology in 2019 Q2 according to their latest regulatory filings, with 42 funds opening new positions, 47 increasing their positions, 40 reducing their positions, and 11 closing their positions.
695% more call options, than puts
Call options by funds: $8.59M | Put options by funds: $1.08M
282% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 11
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
57% more capital invested
Capital invested by funds: $938M → $1.47B (+$535M)
25% more funds holding
Funds holding: 117 → 146 (+29)
18% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 40
2.97% less ownership
Funds ownership: 99.29% → 96.32% (-3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$41.9M |
| 2 |
DM
Deerfield Management
New York
|
+$29.1M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$21M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$20.2M |
| 5 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
+$13.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$34.9M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$33.7M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$13.8M |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$13.5M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$13.1M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CC
151
Clearline Capital
New York
| – | -$337K | -24,723 | Closed |
|
|
DTL
152
Dynamic Technology Lab
Singapore
| – | -$295K | -21,630 | Closed |
|
|
KSCM
153
Kamunting Street Capital Management
Miami Beach,
Florida
| – | -$205K | -15,000 | Closed |
|
154
SG Americas Securities
New York
| – | -$108K | -7,916 | Closed |
|
|
NWM
155
Northwest Wealth Management
Spencer,
Iowa
| – | -$23K | -1,700 | Closed |
|
|
PRC
156
Pearl River Capital
Niles,
Michigan
| – | -$6K | -400 | Closed |
|
CHRS Hedge Fund Activity: Q2 2019 in Review
146 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q2 2019, worth a combined $1.47B — up 57% from $938M a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new CHRS positions and 11 closed out — a net gain of 31 holders — while 47 added to existing stakes and 40 trimmed.
The largest buyer was Lord, Abbett & Co, opening a new position worth an estimated $41.9M. The largest seller was Citadel Advisors, cutting an estimated $34.9M.
- 146 institutional investors held Coherus Oncology (CHRS) as of Q2 2019, up from 117 in Q1 2019.
- Funds reported $1.47B of Coherus Oncology stock for Q2 2019, up 57% quarter-over-quarter.
- 42 funds opened new Coherus Oncology positions in Q2 2019 and 11 closed out, a net change of +31 holders.
- The largest Coherus Oncology buyer in Q2 2019 was Lord, Abbett & Co, an estimated $41.9M added.
- The largest Coherus Oncology seller in Q2 2019 was Citadel Advisors, an estimated $34.9M sold.
Based on aggregated 13F filings for Q2 2019.